ArticleEuropean journal of immunology2017
A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Article in European journal of immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.European journal of drug metabolism and pharmacokinetics · 2020Trial
- Dual BAFF and APRIL inhibition with TACI-Fc depletes IgA plasma cells and ameliorates lupus nephritis.iScience · 2026Article
- Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation.Clinical kidney journal · 2025Article
- Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.Frontiers in immunology · 2025Review
- Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.Frontiers in immunology · 2025Article
- Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The circadian clock gene BMAL1 modulates autoimmunity features in lupus.Frontiers in immunology · 2024Article
- The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies.Frontiers in nephrology · 2023Review
- Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues.Frontiers in immunology · 2023Review
- HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage.Arthritis research & therapy · 2022Article
- Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.Digestive diseases and sciences · 2022Review
- Kinetics of free and ligand-bound atacicept in human serum.Frontiers in immunology · 2022Article
- Article
- BAFF inhibition in SLE-Is tolerance restored?Immunological reviews · 2019Review
- APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice.Transplantation · 2019Article
- Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.PloS one · 2019Article
- Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model.PloS one · 2019Article
- Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme.Rheumatology advances in practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TNF family cytokines B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) support plasma cell survival. It is known that inhibitors of BAFF only (BAFFR-Fc) or BAFF and APRIL (TACI-Fc) administered early enough in an NZB/NZW F1 mouse model of systemic lupus erythematosus (SLE) ameliorate clinical outcomes, pointing to a pathogenic role of BAFF. In the present study, TACI-Fc administrated at a later stage of disease, after onset of autoimmunity, decreased the number of bone marrow plasma cells and slowed down further formation of autoantibodies. TACI-Fc prevented renal damage during a 12-week treatment period regardless of autoantibody levels, while BAFFR-Fc did not despite a similar BAFF-blocking activity in vivo. TACI-Fc also decreased established plasma cells in a T-dependent hapten/carrier immunization system better than single inhibitors of BAFF or APRIL, and sometimes better than combined single inhibitors with at least equivalent BAFF and APRIL inhibitory activities. These results indicate that TACI-Fc can prevent symptoms of renal damage in a mouse model of SLE when BAFFR-Fc cannot, and point to a plasticity of plasma cells for survival factors. Targeting plasma cells with TACI-Fc might be beneficial to prevent autoantibody-mediated damages in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.